Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

others, the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials will not be successful or confirm earlier clinical trial results, including the risk that the survival benefit will not be confirmed by a Phase 3 clinical trial, risks associated with obtaining funding from third parties or completing a financing necessary to support the costs and expenses of a Phase 3 clinical trial, the timing and costs of clinical trials and regulatory approvals will be different than management currently anticipates, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for fiscal year 2008. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.


'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)... Conference Call on Thursday, November 5, 2009 at ...OUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Ph... (NASDAQ: OGXI ) today reported unaudited financi...nded September 30, 2009 and reviewed the Company,s...he following consolidated results reflect the oper...
(Date:11/5/2009)... SUNNYVALE, Calif., Nov. 5 /PRNewswire-FirstCall/ ...ts executives will be speaking at the following in...cipate via webcast. , , Credit Sui... Thursday, 12 November, 2009 at 10 a.m. Mount...r Program, London, England, Tuesda...
(Date:11/5/2009)... FREMONT, Calif., Nov. 5 ...BS), a leading developer of state-of-the-art genet...her Sears, Ph.D. has joined the company,s Scientif... designing and commercializing novel molecular dia...ns, and on the development of computational biolog...
(Date:11/5/2009)... Drug safety specialty firm Bi...rning and Informatics earned the Certified Profess...edential from the American Society for Training an...helle Flewell has more than fifteen years of medic...nce and is responsible for the development of the ...
Breaking Biology Technology:OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8Cepheid to Webcast Upcoming Financial Presentations 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 2BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 3BioSoteria eLearning Executive Michelle Nolin Flewell Earns Certification 4
...rse transcription-polymerase chain reaction (RT-PC...mplate to yield abundant double-stranded DNA produ...s of gene expression and for characterization of R...t as either one-step RT-PCR, in which all reagents...cted sequentially in this tube (1,3) or two-step ...
...pose , The peroxisome is a cellular orga...functions, including the beta-oxidation of very lo...s are characterized by impaired, reduced or total ...in the accumulation of VLCFAs, such as tetracosano...s of these disorders are characterized by the accu...
... the advent of liquid chromatography/ mass spectro...unction in mass spectrometry, it has become possib...g their parents during metabolic stability studies...njection. , Abstract , The Q TR...path and is capable of doing conventional multiple...
Other Biology Technology:Simple Approaches for Optimization of RT-PCR 2Simple Approaches for Optimization of RT-PCR 3Simple Approaches for Optimization of RT-PCR 4Simple Approaches for Optimization of RT-PCR 5A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 2A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 3A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 2Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 3Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 4Simultaneously characterizing and quantifying chloramphenicol and its metabolite using LC/MS/MS 5
(Date:11/6/2009)...ills, MI-based Law Enforcement Intelligent Devices...and patent-pending Biometric Access Control System...uman Services, National Institutes of Health (NIH)...pport the NIH,s entire police force that is respon... agency. The project is expected to be completed ...
(Date:11/5/2009)... (NABT) will recognize Leonard C. Yannielli, profe...mmunity College (NVCC) in Waterbury, Connecticut, ... NABT annual professional development conference t... , The Evolution Education Award is cosponsored ...(AIBS) and Biological Sciences Curriculum Study (B...
(Date:11/5/2009)...ining grant in the amount of $2,756,719 by the Nat...duation Education and Research Training (IGERT) pr... to Kent State. The grant, which is funded under t... runs through 2014. , The grant funds an IGERT p...e sensing (EARS). The purpose of the program is to...
Breaking Biology News(10 mins):Biologists, educators recognize excellence in evolution education 2Kent State receives $2.7 million NSF training grant for environmental aquatic resource sensing 2Fructose May Raise Blood Pressure 60389 1Fructose May Raise Blood Pressure 60389 2Texas State University Names Developer of ALKA V6 Compound to Board of Advisors 60385 1Texas State University Names Developer of ALKA V6 Compound to Board of Advisors 60385 2Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 1Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 2
...ansas Natalie Ciaccio, a fourth-year graduate stu...l Chemistry at the University of Kansas, is invest...cer drug therapy, and she is focusing her work on ... Institute estimates that in 2008, there were 21,8...tem disorders in the United States. These cancers ...
...MA -- Three leading research centers based in Wood...e Woods Hole Consortium, a new alliance that will ...ome of the major issues facing society today and s...South Coast of Massachusetts. , The consortium co...y (MBL), Woods Hole Oceanographic Institution (WHO...
...ys of Charles Darwin, researchers are interested i...tanding the development of animal and plant specie...f vertebrates, this research has already come quit... the relationships between the animal groups that ...istory, probably in the late Precambrian, some 650...
Other Biology News:University of Kansas graduate student researcher takes aim at deadly brain tumors 2University of Kansas graduate student researcher takes aim at deadly brain tumors 33 Woods Hole scientific institutions forge alliance to address societal issues 23 Woods Hole scientific institutions forge alliance to address societal issues 3Early family ties: No sponge in the human family tree 2Early family ties: No sponge in the human family tree 3
...werPac 3000 power supply, 220-240 V, is used for p... isoelectric focusing (IEF). The system includes b... chambers, chassis, harvesting apparatus, cooling ...pply, 10 ml Bio-Lyte ampholytes (pH 3-10), 60 ml s...
Anti-Connexin 45 (Cx45), Near C-terminus, cytoplasmic Monoclonal Antibody, Unconjugated, Clone 5B9.2 from CHEMICON
NBT/BCIP Chromogen System (SIGNET) from Covance Research Products, Inc
...eaders combines reagent dispensing with fluorescen...ordable, easy-to-use platform for the complete ran...r design and adaptability of the Infinite 200 seri...omator (M200) or filter (F200) system and allows y...
Biology Products: